Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs PT Telekomunikasi Indonesia Tbk (TLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs PT Telekomunikasi Indonesia Tbk — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while PT Telekomunikasi Indonesia Tbk trades at $12.71 (market cap $12.31B). The key difference: PT Telekomunikasi Indonesia Tbk is the larger of the two by market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.66% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and PT Telekomunikasi Indonesia Tbk for 1 Days on average.
| SYRE | TLK | |
|---|---|---|
Market Cap | $7.52B | $12.31B |
Volume | 1,441,031 | 964,895 |
Sector | Health | Media |
52-Week High | $108.92 | $23.43 |
52-Week Low | $22.18 | $12.42 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $6.52B | $13.67B |
Dividend Yield | — | 9.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →
